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INTRODUCTION 
Anthracycline antibiotics is one of the effective medicine 
against cancer and despite this benefit, they have some 
irreversible cardiomyopathy side effect with distribution 
of 5-20% and then medicine treatment has no effect on its 
improvement and has the mortality of more than 50%. 
So, preventing cardiomyopathy has clinical importance. 
Acute poisoning is just like myocardia and may cause 
congestive heart failure. Dilatory cardiomyopathy is 
considered with some signs and symptoms like fatigue, 
activity shortness of breath, orthopnea, bradycardia and 
pulmonary edema. In Echocardiography, firstly the 
diastolic dysfunction disorder and then systolic 
ABSTRACT 
 
Background: Anthracycline antibiotics are potent antineoplastic agents. Unfortunately, despite its broad 
effectiveness, anthracycline therapy is associated with irreversible dilated cardiomyopathy. Toxic effect may occur at 
any stage of anthracycline treatment. When it takes place, medical therapy is mostly insufficient. Therefore, 
prevention of cardiomyopathy has great clinical importance. This study aimed at evaluating the protective effect of 
carvedilol against anthracycline-induced cardiomyopathy on patients with breast cancer and lymphoma.  
Methods: In a randomized clinical trial, 66 patients with breast cancer or lymphoma selected for chemotherapy in 
Tabriz city hospital. These patients randomized in three groups; the first group (control) received placebo; the second 
group (A) received carvedilol 6.25mg/d and the third group (B) received carvedilol 12.5mg/d for 4months. 
Conventional echocardiography and tissue Doppler study were employed for evaluating the patients on the baseline 
and at the end of survey.  
Results: At the end of 4 months of follow-up, 1 (4.5%) patient in group B, 2 (9.1%) patients in group A and 4 
(18.2%) patients of the control group had died. Clinical systolic dysfunction was encountered in 5 (27.8%), 5 (25%) 
and 1 (4.8%) patients in the control, A and B groups, respectively. A distinctive clinical diastolic dysfunction was 
encountered in 5 (27.8%), 3 (15%) and 3 (14.3%) patients in the control, A and B groups, respectively. Carvedilol 
with a dose of 6.25mg/d prohibited the diastolic dysfunction at the end of study without a significant effect on the 
prevention of diastolic dysfunction. Carvedilol with a dose of 12.5mg/d effectively prevented both the systolic and 
diastolic dysfunctions at the end of study. 
Conclusions: The current study showed that prophylactic administration of carvedilol with a dose of 12.5 mg/d might 
significantly prevent the systolic and diastolic dysfunction of the left ventricle in patients receiving chemotherapy 
with anthracycline.  
  
Keywords: Anthracycline, Carvedilol, Cardiomyopathy 
1Department of Internal Medicine, Faculty of Medicine, Ardabil University of Medical Science, Ardabil, Iran 
2Department of Cardiology, Madani Hospital, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, 
Iran 
 
Received: 04 November 2017 
Accepted: 29 November 2017 
 
*Correspondence: 
Dr. Bijan Zamani, 
E-mail: bijan.zamani2016@gmail.com 
 
Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under 
the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial 
use, distribution, and reproduction in any medium, provided the original work is properly cited. 
DOI: http://dx.doi.org/10.18203/2349-3933.ijam20180061 
Zamani B et al. Int J Adv Med. 2018 Feb;5(1):16-20 
                                                   International Journal of Advances in Medicine | January-February 2018 | Vol 5 | Issue 1    Page 17 
dysfunction disorder can be observed specially with the 
movement of left ventricular septal.1  
Early recognition of cardiotoxicity is so important in 
preventing cardiomyopathy. Lack of 10% of left 
ventricular ejection fraction (EF) with dose of 200 mg/m2 
of body surface of Doxorubicin has specificity of 72% 
and sensitivity of 90% in cardiotoxicity diagnosis.2 The 
mechanism of cardiotoxicity includes Apoptosis, free 
radicals of oxygen, mitochondria dysfunction disorder 
and activation of metalloproteinase matrix. Carvedilol in 
addition to effect on Beta 1, 2 and Alfa had some 
antioxidant property that has been confirmed in several 
studies on animal on very limited on human.3 
The aim of this study was to investigate the effect of 
prescribing prophylactic carvedilol on incidence of 
cardiomyopathy resulted from anthracyclines.  
METHODS 
In this randomized clinical trial study, 66 people were 
selected who were treated under anthracycline program 
by recognition of lymphoma and breast cancer and has 
been referred to Tabriz city hospital from June 2012 to 
June 2013 and followed up for 4months. The candidate 
patients for chemotherapy were randomly divided into 
three groups each with 22 cases. The first, second and 
third group took Placebo, 6.25 and 12.5mg/day of 
carvedilol, respectively. This prescription started 24hours 
before chemotherapy and lasted for 4months. Both 
patients and the person presenting medicine or placebo 
were blinded. The patients in this study, were under 
echocardiography and tissue Doppler by Vingmed 
System® CV 75.  
The function of left ventricular was measured during 
diastole and systole before chemotherapy and during 
acute phase and in case of clinical signs and during acute 
phase in fourth months and in order to exact computation 
of EF, Anoles speed of Mitral valve was used.  
The above information was compared before and after 
chemotherapy. The total amount of medicine used in 
breast cancer was 360mg doxorubicin and/or 600mg 
epirubicin. The total amount of medicine used in non-
Hodgkin Lymphoma was 400mg doxorubicin and in 
Hodgkin lymphoma it was 300mg.  
The patients with the history of chemotherapy, 
radiotherapy, congestive heart Failure disorder or 
congestive and limited fixed cardiomyopathy, coronary 
artery disease, medium to severe disorder of mitral valve 
and aortic in primary echocardiography, branch block, 
thyroid dysfunction disorder and prohibition of 
prescription of carvedilol and simultaneous serious 
disease and patients using ACEI, ARB, diuretic and beta 
blocker, age <12years old and poor-view patients to echo 
were excluded from study. 
The price of carvedilol and the cost of echocardiography 
and tissue doppler has been paid by the research grant 
and written consent was taken from the patients. 
Collected data were analyzed as Mean ±SD, frequency 
and percent in SPSS program version 16. p<0.05 was 
statistically considered meaningful.  
RESULTS 
The frequency of mortality rate in control group was 
18.2%, in 6.25mg carvedilol group was 9.1% and in 
12.5mg carvedilol group was 4.5% and not meaningfully 
different. The average age of control group was 
27/15±50/43 (74-19) years old, the 6.25mg carvedilol 
group was (76-17) 16/14±70/45years old, and 12.5mg 
carvedilol group was 00/11±52/52 (68-33) and there is no 
statistically meaningful difference between three groups. 
There is no statistically meaningful difference between 3 
groups in term of gender and the type of cancer. The 
average of aggregation dose of Adriamycin in control 
group was 12/23±34/394mg/m2, in 6.25mg carvedilol 
group was 43/12±45/378mg/m2 and in 12.5mg Carvedilol 
group was 45/12±23/387mg/m2 and there was no 
statistically meaningful difference between three groups. 
The average aggregation dose of Epirubicin in control 
group was 34/12±12/556mg/m2, in 6.25mg carvedilol 
group was 23/14±25/576 and in 12.5mg carvedilol group 
was 17/17±54/576mg/m2 and there was no statistically 
meaningful difference between three groups. 
 
Table 1: Echocardiography and basic tissue doppler in patients of three groups. 
Groups Variables Control Carvedilol 6.25mg Carvedilol 12.5mg P-value 
LVEF (%) 62/56±3/58  07/35±5/60  06/00±7/61  38/0  
Diameter of LVDD (mm) 61/13±0/4  39/17±0/4  34/93±0/3  23/0  
Diameter of LVSD (mm) 35/00±0/3  44/92±0/2  29/73±0/2  07/0  
E wave speed (cm/s) 67/5±14/68  71/15±13/75  04/38±5/67  09/0  
E/a ratio  45/99±0/0  21/03±0/1  17/83±0/0  09/0  
Maxillary systolic velocity  
of mitral valve (cm/s) 
38/56±2/17  77/25±2/17  92/33±2/17  94/0  
EI/EA 02/53±1/3  97/37±0/3  66/69±0/3  52/0  
Spreading speed (cm/s) 17/72±8/58  78/90±10/65  09/38±12/66  05/0  
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There was no statistically meaningful difference of 
frequency of pure systole cardiomyopathy and diastole 
cardiomyopathy between 3 groups. The percent of 
frequency of systole cardiomyopathy after chemotherapy 
in control group was 27.8% and in experiment (carvedilol 
acceptors) was 14.7% and it was not statistically 
meaningful. The percent of frequency of pure diastole 
cardiomyopathy after chemotherapy in control group was 
27.8% and in experiment group was 14.6% and not 
statistically meaningful. 
According to results of echocardiography and basic tissue 
Doppler (before chemotherapy), left ventricular ejection 
fraction (p=0.375), end-diastolic diameter of left 
ventricular (p-0.226), the end-systolic diameter of left 
ventricular (p-0.069), speed of wave E (p-0.086), E/A 
ratio (p=0.087), the peak systole speed of Mitral valve 
(p=0.939), Ei/Ea ratio (p=0.518) and Spreading speed 
(p=0.053) had no statistically meaningful difference 
among three groups (Table 1). 
After 4 months of chemotherapy, based on results of 
echocardiography and doppler, it is recognized that in 
control group the average changes of the peal systolic 
speed of mitral valve (p=0.135) and Ei/Ea ratio (p=0.245) 
after chemotherapy was not statistically meaningful 
compared to the basic amounts. The average end-diastolic 
diameter of left ventricular (p=0.012) and the end-systolic 
diameter of left ventricular (p=0.003) after chemotherapy 
meaningfully increased compared to basic amounts. The 
average left ventricular ejection fraction (p<0.001), the 
speed of wave E (p=0.048), E/A ratio (p-0.023) and speed 
development (p=0.048) after chemotherapy meaningfully 
decreased compared to basic amounts.  
In carvedilol groups the average changes of end-systolic 
diameter of left ventricular (p=0.104), the speed of wave 
E (p=0.068), E/A ratio (p=0.632), the peak systolic speed 
of Mitral valve (p=0.149), Ei/Ea ratio (p=0.493), 
posterior and anterior movement of Mitral valve 
(p=0.462) and Spreading speed (p=0.220) after 
chemotherapy was not statistically meaningful compared 
to basic amounts. The average ejection fraction and end-
diastolic diameter of left ventricular after chemotherapy 
meaningfully decreased compared to basic amounts 
(Table 2). 
 
Table 2: Echocardiography and basic tissue Doppler in patients of three groups 4 month after Chemotherapy. 
Groups Variables Control Carvedilol 6.25mg Carvedilol 12.5mg P-value 
LVEF (%) 80/94±3/53  76/15±7/53  20/81±6/56  0 
Diameter of LVDD (mm) 57/56±0/4  46/50±0/4  37/09±0/4  01/0  
Diameter of LVSD (mm) 44/24±0/3  55/00±0/3  35/85±0/2  0 
E wave speed (cm/s) 71/1±10/63  68/35±12/71  03/43±5/66  04/0  
E/a ratio  33/86±0/0  38/00±0/1  17/81±0/0  02/0  
Maxillary systolic velocity of mitral valve (cm/s) 50/61±1/16  24/05±3/17  34/38±4/15  14/0  
EI/EA 78/88±0/3  80/51±0/3  66/79±0/3  25/0  
Spreading speed (cm/s) 83/17±8/52  58/95±9/62  80/90±9/64  04/0  
 
DISCUSSION 
In this paper, carvedilol was prescribed in 6.25 and 12.5 
mg/day for four months. However, in the end of study, 
the percent of frequency of pure systolic and diastolic 
cardiomyopathy after chemotherapy in carvedilol group 
was less than control group (27.8% versus 14.6%) but the 
difference was not statistically meaningful.  
On the other hand, the investigation by 2-dimentional 
echocardiography and color doppler showed that 
prescription of carvedilol in 6.25mg/day has a protective 
effect toward diastolic disorder and with 12.5mg/day has 
a protective effect toward both diastolic and systolic 
disorder. 
Matusi et al in a study on animals (rat) showed that 
carvedilol prescription may have a preventing effect 
toward cardiomyopathy of doxorubicin.4 In another study 
on animals by Santos et al, it was shown that prescription 
of prophylactic carvedilol can prevent mitochondrial 
cardiomyopathy of doxorubicin.5 Spallarossa et al 
showed in an animal study that prescription of 
prophylactic carvedilol can prevent cardiomyopathy of 
doxorubicin.6 Cruz et al in a study on Hamster showed 
that prescription of carvedilol in 1 mg/day for each 
kg/day can improve heart function.7 
As we can see, above investigations has confirmed the 
protective effect of carvedilol in animal models. Only in 
2 studies the effect of carvedilol on treatment or 
prevention of cardiomyopathy caused by chemotherapy 
has been considered. 
Kalay et al in a study in turkey studied 50 patients with 
lymphoma or breast cancer randomly in two carvedilol 
groups (12.5mg/day) and placebo. In this study, 
Echocardiography and Transmitral pulsed Doppler was 
used before chemotherapy and in the end of 6th month of 
study in order to determine the systolic and diastolic 
Zamani B et al. Int J Adv Med. 2018 Feb;5(1):16-20 
                                                   International Journal of Advances in Medicine | January-February 2018 | Vol 5 | Issue 1    Page 19 
function of left ventricular. It has to be noted both groups 
were matched before chemotherapy. In the end of six 
months, no meaningful difference was observed in 
experimental group as left ventricular ejection fraction 
and diastolic and systolic diameters. Whereas in control 
group, in the end of six months left ventricular ejection 
fraction meaningfully decreased and systolic and diastolic 
diameters increased. In study of Doppler results only the 
speed of wave E (E-velocity) in experiment group 
meaningfully decreased. Whereas in control group in 
addition to the E-velocity, E/A ratio decreased, too. In the 
other hand, it was shown in this study that carvedilol with 
mentioned dose has a protective effect toward systolic 
and diastolic disorder of left ventricular caused by 
Anthracyclines.8 
As it was mentioned before, the protective effect toward 
both systolic and diastolic disorder was observed in 
12.5mg daily and in 6.25mg only the diastolic function of 
left ventricular was protected. It has to be considered that 
based on MOCHA guideline the proposed dose of 
carvedilol in patients with heart disorders is 12.5 to 
50mg.5 
There isn't a full agreement about a proper dose of 
carvedilol in chronic artery patients. Especially that the 
protective effect of this medicine has not been widely 
investigated on cardiomyopathy caused by chemotherapy 
yet and more research is needed.8 
Low sample size and lack of long-term effects of 
anthracycline in heart diseases are two main limitation in 
Kalay et al study and also in our study. However, this 
study has two advantages: evaluation of tissue Doppler 
parameters in addition to using popular echocardiography 
for patients and using two different doses of carvedilol 
and compare them. 
According to the results of present study, the prescription 
of carvedilol with dose of 12.5milligram per day can have 
protective effect toward systolic and diastolic disorder of 
left ventricular. Although the percent of frequency of 
clinical cardiomyopathy in studied groups has no 
meaningful difference. It has to be considered that the 
most important reason for no meaningful difference is 
low sample size despite the obvious difference between 
groups.8 
In present study, for four month observing patients, the 
mortality rate in control group, carvedilol group with 
dose of 6.25mg/day and 12.5mg/day were 16, 8 and 4 per 
100000, respectively. In Kalay et al study, the mortality 
rate in control and experimental group was reported 16 
and 4 per 100000, respectively which is not statistically 
meaningful. It also concluded that although this 
difference is not statistically meaningful but 
considerable.8 
On the other hand, Mukai et al in Japan investigated the 
effect of prescription of carvedilol with initial dose of 
2mg/day and increase to 10-20mg/day in 5 patients with 
cardiomyopathy from anthracycline. It is shown in this 
paper that the prescription of carvedilol can improve the 
symptoms of patients, ventricular function and diastolic 
and systolic diameters.9n This is in contrast with the 
papers that found out the cardiomyopathy from 
anthracycline is irreversible.10 
CONCLUSION 
The prescription of carvedilol with two doses of 6.25 and 
12.5mg/day may decrease the findings of 
echocardiography and tissue doppler for diastolic and 
systolic disorder. Therefore, according to the possible 
effect of carvedilol in preventing myopathy of 
chemotherapy, so, it seems that further studiers with more 
samples clarifies more detailed results. 
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